Cargando…
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
BACKGROUND: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is impair...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1821019/ https://www.ncbi.nlm.nih.gov/pubmed/17341317 http://dx.doi.org/10.1186/1465-9921-8-19 |
_version_ | 1782132668165521408 |
---|---|
author | Haney, Sarah Hancox, Robert J |
author_facet | Haney, Sarah Hancox, Robert J |
author_sort | Haney, Sarah |
collection | PubMed |
description | BACKGROUND: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is impaired. We assessed the effect of long-acting beta-agonist treatment on the response to 5 mg nebulised salbutamol and to ipratropium bromide. METHODS: Two double-blind, placebo-controlled, crossover studies of inhaled formoterol 12 μg twice daily in patients with asthma. High-dose salbutamol: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled methacholine to produce a 20% fall in FEV(1). Salbutamol 5 mg was then administered via nebuliser and the FEV(1 )was monitored for 20 minutes. Ipratropium: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled 4.5% saline to produce a 20% fall in FEV(1). Salbutamol 200 μg or ipratropium bromide 40 μg was then inhaled and the FEV(1 )was monitored for 30 minutes. Four study arms compared the response to each bronchodilator after formoterol and placebo. Analyses compared the area under the bronchodilator response curves, adjusting for changes in pre-challenge FEV(1), dose of provocational agent and FEV(1 )fall during the challenge procedure. RESULTS: The response to nebulised salbutamol was 15% lower after formoterol therapy compared to placebo (95% confidence 5 to 25%, p = 0.008). The response to ipratropium was unchanged. CONCLUSION: Long-acting beta-agonist treatment induces tolerance to the bronchodilator effect of beta-agonists, which is not overcome by higher dose nebulised salbutamol. However, the bronchodilator response to ipratropium bromide is unaffected. |
format | Text |
id | pubmed-1821019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-18210192007-03-14 Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials Haney, Sarah Hancox, Robert J Respir Res Research BACKGROUND: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is impaired. We assessed the effect of long-acting beta-agonist treatment on the response to 5 mg nebulised salbutamol and to ipratropium bromide. METHODS: Two double-blind, placebo-controlled, crossover studies of inhaled formoterol 12 μg twice daily in patients with asthma. High-dose salbutamol: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled methacholine to produce a 20% fall in FEV(1). Salbutamol 5 mg was then administered via nebuliser and the FEV(1 )was monitored for 20 minutes. Ipratropium: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled 4.5% saline to produce a 20% fall in FEV(1). Salbutamol 200 μg or ipratropium bromide 40 μg was then inhaled and the FEV(1 )was monitored for 30 minutes. Four study arms compared the response to each bronchodilator after formoterol and placebo. Analyses compared the area under the bronchodilator response curves, adjusting for changes in pre-challenge FEV(1), dose of provocational agent and FEV(1 )fall during the challenge procedure. RESULTS: The response to nebulised salbutamol was 15% lower after formoterol therapy compared to placebo (95% confidence 5 to 25%, p = 0.008). The response to ipratropium was unchanged. CONCLUSION: Long-acting beta-agonist treatment induces tolerance to the bronchodilator effect of beta-agonists, which is not overcome by higher dose nebulised salbutamol. However, the bronchodilator response to ipratropium bromide is unaffected. BioMed Central 2007 2007-03-06 /pmc/articles/PMC1821019/ /pubmed/17341317 http://dx.doi.org/10.1186/1465-9921-8-19 Text en Copyright © 2007 Haney and Hancox; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Haney, Sarah Hancox, Robert J Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials |
title | Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials |
title_full | Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials |
title_fullStr | Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials |
title_full_unstemmed | Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials |
title_short | Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials |
title_sort | overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. two randomised controlled trials |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1821019/ https://www.ncbi.nlm.nih.gov/pubmed/17341317 http://dx.doi.org/10.1186/1465-9921-8-19 |
work_keys_str_mv | AT haneysarah overcomingbetaagonisttolerancehighdosesalbutamolandipratropiumbromidetworandomisedcontrolledtrials AT hancoxrobertj overcomingbetaagonisttolerancehighdosesalbutamolandipratropiumbromidetworandomisedcontrolledtrials |